Nyxoah to Release First Quarter 2026 Financial Results on May 12, 2026

Mont-Saint-Guibert, Belgium – April 28, 2026, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the first quarter of 2026 on Tuesday, May 12, 2026. Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET / 4:30pm ET.

A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyxoah's Q1 2026 Earnings Call Webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast.

If you plan to ask a question, please use the following link: Nyxoah's Q1 2026 Earnings Call. After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call.

The archived webcast will be available for replay shortly after the close of the call.

About Nyxoah

Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the FDA for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device.

Forward-looking statements

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or management’s current expectations regarding the Genio system; the potential advantages of the Genio system; Nyxoah’s goals with respect to the potential use of the Genio system; the Company's commercialization strategy and entrance to the U.S. market; the Company's results of operations, financial condition, liquidity, performance, prospects, growth, future revenue, future operating expenses, future gross margins and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on March 26, 2026 and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward- looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Contacts:
Nyxoah
John Landry, CFO
[email protected]

Rémi Renard
Head of Investor Relations & Corporate Communication
[email protected]

Attachment

• ENGLISH_1Q26 Earnings Call Announcement

GLOBENEWSWIRE (Distribution ID 1001178540)

Nyxoah Publiera ses Résultats Financiers du Premier Trimestre 2026 le 12 Mai 2026

Mont-Saint-Guibert, Belgique – 28 avril 2026, 22h05 CET / 16h05 ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (« Nyxoah » ou la « Société »), une société de technologie médicale développant des alternatives thérapeutiques révolutionnaires pour l'apnée obstructive du sommeil (AOS) par la neuromodulation, a annoncé aujourd'hui que la Société publiera ses résultats financiers du premier trimestre 2026 le mardi 12 mai 2026. Le management de la Société tiendra une conférence téléphonique pour commenter ces résultats ce jour-là, à partir de 22h30 CET / 16h30 ET.

Une retransmission en ligne de la conférence sera accessible via la page Relations investisseurs du site web de Nyxoah ou via ce lien : Nyxoah's Q1 2026 Earnings Call Webcast. Pour ceux qui ne prévoient pas de poser de question à la direction, la Société recommande d'écouter la conférence via la retransmission en ligne.

Si vous prévoyez de poser une question, veuillez utiliser le lien suivant : Nyxoah's Q1 2026 Earnings Call. Une fois inscrit, vous recevrez un e-mail contenant les informations de connexion et le code d'accès unique à la conférence téléphonique nécessaire pour participer à la conférence en direct. Afin de vous assurer d'être connecté avant le début de la conférence, la Société vous recommande de vous inscrire au moins 10 minutes avant le début de la conférence.

La retransmission archivée sera disponible peu après la fin de la conférence.

À propos de Nyxoah

Nyxoah opère dans le secteur des technologies médicales. Elle se concentre sur le développement et la commercialisation de solutions innovantes destinées à traiter le Syndrome d’Apnées Obstructives du Sommeil (SAOS). La principale solution de Nyxoah est le système Genio^®, une thérapie de neurostimulation du nerf hypoglosse sans sonde et sans batterie qui a reçu le marquage CE, centrée sur le patient et destinée à traiter le Syndrome d’Apnées Obstructives du Sommeil (SAOS), le trouble respiratoire du sommeil le plus courant au monde. Ce dernier est associé à un risque accru de mortalité et des comorbidités, dont les maladies cardiovasculaires. La visions de Nyxoah est que les patients souffrant de SAOS doivent pouvoir profiter de nuits réparatrices et vivre pleinement leur vie.

À la suite de la finalisation probante de l’étude BLAST OSA, le système Genio^® a reçu le marquage européen CE en 2019. Nyxoah a réalisé avec succès deux IPO : l’une sur Euronext Bruxelles en septembre 2020 et l’autre sur le NASDAQ en juillet 2021. Grâce aux résultats positifs de l'étude BETTER SLEEP, Nyxoah a reçu le marquage CE pour l’extension de ses indications thérapeutiques aux patients souffrant de collapsus concentrique complet (CCC), pour lesquels les thérapies concurrentes sont actuellement contre-indiquées. En outre, la Société a annoncé les résultats positifs de l'étude pivot DREAM IDE et l'obtention de l'autorisation de la FDA pour un sous-groupe de patients adultes atteints d'AOS modérée à sévère avec un IAH supérieur ou égal à 15 et inférieur ou égal à 65.

Pour plus d’informations, visitez www.nyxoah.com

Attention – Marquage CE depuis 2019. Approuvé par la FDA en août 2025 en tant que dispositif disponible uniquement sur prescription médicale.

DÉCLARATIONS PROSPECTIVES

Certaines déclarations, convictions et opinions contenues dans le présent communiqué de presse sont de nature prospective et reflètent les attentes actuelles de la Société ou, le cas échéant, de ses administrateurs ou de sa direction concernant le système Genio ; les avantages potentiels du système Genio ; les objectifs de Nyxoah concernant l'utilisation potentielle du système Genio ; la stratégie de commercialisation de la Société et son entrée sur le marché américain ; les résultats d'exploitation, la situation financière, la liquidité, la performance, les perspectives, la croissance, les revenus futurs, les charges d'exploitation futures, les marges brutes futures et les stratégies de la Société. De par leur nature, les déclarations prospectives comportent un certain nombre de risques, d’incertitudes, d’hypothèses et d’autres facteurs susceptibles d’entraîner une différence significative entre les résultats ou événements réels et ceux exprimés ou sous-entendus dans les déclarations prospectives. Ces risques, incertitudes, hypothèses et facteurs pourraient avoir un impact négatif sur l’issue et les conséquences financières des projets et événements décrits dans le présent document. Ces risques et incertitudes comprennent, sans s’y limiter, les risques et incertitudes exposés dans la section « Facteurs de risque » du rapport annuel de la Société sur le formulaire 20-F pour l’exercice clos le 31 décembre 2025, déposé auprès de la Securities and Exchange Commission (« SEC ») le 26 mars 2026, ainsi que dans les rapports ultérieurs que la Société dépose auprès de la SEC. Une multitude de facteurs, y compris, sans s'y limiter, les changements dans la demande, la concurrence et la technologie, peuvent entraîner des événements, des performances ou des résultats réels sensiblement différents de toute évolution prévue. Les déclarations prospectives contenues dans le présent communiqué de presse concernant des tendances ou des activités passées ne constituent pas des garanties de performances futures et ne doivent pas être interprétées comme une assurance que ces tendances ou activités se poursuivront à l'avenir. En outre, même si les résultats ou les développements réels correspondent aux déclarations prospectives contenues dans le présent communiqué de presse, ces résultats ou développements ne sont pas nécessairement indicatifs des résultats ou développements à venir. Aucune déclaration ni garantie n'est faite quant à l'exactitude ou à l'équité de ces déclarations prospectives. En conséquence, la Société décline expressément toute obligation ou engagement de publier des mises à jour ou des révisions des déclarations prospectives contenues dans le présent communiqué de presse à la suite d'un changement dans les attentes ou d'un changement dans les événements, conditions, hypothèses ou circonstances sur lesquels ces déclarations prospectives sont fondées, sauf si la loi ou la réglementation l'exige expressément. Ni la Société, ni ses conseillers ou représentants, ni aucune de ses filiales, ni les dirigeants ou employés de ces entités ne garantissent que les hypothèses sous-jacentes à ces déclarations prospectives sont exemptes d'erreurs, et n'acceptent aucune responsabilité quant à l'exactitude future des déclarations prospectives contenues dans le présent communiqué de presse ou à la réalisation effective des développements prévus. Vous ne devez pas vous fier indûment aux déclarations prospectives, qui ne sont valables qu'à la date du présent communiqué de presse.

Contacts :

Nyxoah
John Landry, CFO
[email protected]

Rémi Renard
Head of Investor Relations & Corporate Communication
[email protected]

Pièce jointe

• FRENCH_1Q26 Earnings Call Announcement

GLOBENEWSWIRE (Distribution ID 1001178540)

INFORMATION RÉGLEMENTÉE

Publication relative à des notifications de transparence

Mont-Saint-Guibert (Belgique), le 20 mars 2026, 22:30h CET / 17:30h ET – Conformément à l'article 14 de la loi du 2 mai 2007 relative à la publicité des participations importantes, Nyxoah SA (Euronext Brussels/Nasdaq : NYXH) annonce qu’elle a reçu une notification de transparence comme détaillée ci-dessous.

Robert Taub / Robelga SRL

Le 19 mars 2026, Nyxoah a reçu une notification de transparence de Robert Taub et d’une personne liée, Robelga SRL, à la suite du franchissement à la hausse du seuil de 3% par Robelga SLR le 30 décembre 2025 (sans modification de la participation globale du “groupe”). Sur la base de la notification, Robert Taub (avec ses entreprises contrôlées) détenait 4.360.800 droits de vote, soit 4.310.800 droits de vote attachés à des titres et 50.000 instruments financiers assimilés, représentant 10,14% du nombre total des droits de vote en date du 30 décembre 2025 (43.026.460).

La notification datée du 19 mars 2026 contient les informations suivantes :

• Motif de la notification : acquisition ou cession de titres conférant le droit de vote ou de droits de vote
• Notification par : une entreprise mère ou une personne détenant le contrôle
• Personnes tenues à la notification :
  • Robert Taub
  • Robelga SRL (avec adresse à Avenue des Croix de Guerre 149 / 13, 1120 Brussels)
• Date du dépassement de seuil : le 30 décembre 2025
• Seuil franchi : 3%
• Dénominateur : 43.026.460
• Détails de la notification :

• Chaine des entreprises contrôlées par l'intermédiaire desquelles la participation est effectivement détenue : Robelga SRL est 100% propriété de BMI Estate (société simple sans personnalité juridique). Robert Taub a 100% l'usufruit et les enfants de Robert Taub ont 100% la nue-propriété de BMI Estate.
• Information supplémentaire : Cette notification était requise en raison du dépassement à la hausse du seuil de 3% par Robelga SRL.

*

* *

Contact:
Nyxoah
John Landry, CFO
[email protected]

Pièce jointe

• 2026 03 20 PR Transparency notification (Robert Taub) (FR)

GLOBENEWSWIRE (Distribution ID 1001171212)

REGULATED INFORMATION

Publication relating to transparency notifications

Mont-Saint-Guibert (Belgium), March 20, 2026, 10:30 pm CET / 5:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below.

Robert Taub / Robelga SRL

On March 19, 2026, Nyxoah received a transparency notification from Robert Taub and related person Robelga SRL, following the crossing above the 3% threshold by Robelga SRL on December 30, 2025 (while the overall “group” participation did not change). Based on the notification, Robert Taub (together with his controlled undertakings) held 4,360,800 voting rights, consisting of 4,310,800 voting rights linked to securities and 50,000 equivalent financial instruments, representing 10.14% of the total number of voting rights on December 30, 2025 (43,026,460).

The notification dated March 19, 2026 contains the following information:

• Reason for the notification: acquisition or disposal of voting securities or voting rights
• Notification by: a parent undertaking or a controlling person
• Persons subject to the notification requirement:
  • Robert Taub
  • Robelga SRL (with address at Avenue des Croix de Guerre 149 / 13, 1120 Brussels)
• Date on which the threshold was crossed: December 30, 2025
• Threshold that is crossed: 3%
• Denominator: 43,026,460
• Notified details:

• Full chain of controlled undertakings through which the holding is effectively held: Robelga SRL is 100% owned by BMI Estate (a partnership (société simple) without legal personality). Robert Taub has 100% usufruct and Robert Taub’s children have 100% bare ownership of BMI Estate.
• Additional information: This notification was due because Robelga SRL moved above the 3% threshold.

*

* *

Contact:
Nyxoah
John Landry, CFO
[email protected]

Attachment

• 2026 03 20 PR Transparency notification (Robert Taub) (ENG)

GLOBENEWSWIRE (Distribution ID 1001171212)

REGULATED INFORMATION

Publication relating to transparency notifications

Mont-Saint-Guibert (Belgium), March 20, 2026, 10:30 pm CET / 5:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below.

Robert Taub / Robelga SRL

On March 19, 2026, Nyxoah received a transparency notification from Robert Taub and related person Robelga SRL, following the crossing above the 3% threshold by Robelga SRL on December 30, 2025 (while the overall “group” participation did not change). Based on the notification, Robert Taub (together with his controlled undertakings) held 4,360,800 voting rights, consisting of 4,310,800 voting rights linked to securities and 50,000 equivalent financial instruments, representing 10.14% of the total number of voting rights on December 30, 2025 (43,026,460).

The notification dated March 19, 2026 contains the following information:

• Reason for the notification: acquisition or disposal of voting securities or voting rights
• Notification by: a parent undertaking or a controlling person
• Persons subject to the notification requirement:
  • Robert Taub
  • Robelga SRL (with address at Avenue des Croix de Guerre 149 / 13, 1120 Brussels)
• Date on which the threshold was crossed: December 30, 2025
• Threshold that is crossed: 3%
• Denominator: 43,026,460
• Notified details:

• Full chain of controlled undertakings through which the holding is effectively held: Robelga SRL is 100% owned by BMI Estate (a partnership (société simple) without legal personality). Robert Taub has 100% usufruct and Robert Taub’s children have 100% bare ownership of BMI Estate.
• Additional information: This notification was due because Robelga SRL moved above the 3% threshold.

*

* *

Contact:
Nyxoah
John Landry, CFO
[email protected]

Attachment

• 2026 03 20 PR Transparency notification (Robert Taub) (ENG)

GLOBENEWSWIRE (Distribution ID 1001171212)

Nyxoah Annonce la Signature d'un Mémorandum d'Accord avec l'Hôpital Sheikh Shakhbout Medical City afin d'Améliorer la Prise en Charge du Traitement de l'AOS et d'Accélérer l'Accès à Genio au Moyen-Orient

Mont-Saint-Guibert, Belgique – 18 février 2026, 22h05 CET / 16h05 ET – Nyxoah SA (Euronext Bruxelles/Nasdaq : NYXH) (« Nyxoah » ou la « Société ») une société de technologie médicale spécialisée dans le développement et la commercialisation de solutions innovantes pour le traitement de l'Apnée Obstructive du Sommeil (« AOS ») par neuromodulation, a annoncé aujourd'hui la poursuite de ses efforts visant à renforcer sa présence au Moyen-Orient grâce à la signature d'un protocole d'accord avec Sheikh Shakhbout Medical City (SSMC), un hôpital phare des Émirats arabes unis spécialisé dans les soins complexes et graves, filiale de PureHealth, le plus grand groupe de soins de santé du Moyen-Orient. Ce protocole d'accord reflète l'orientation stratégique de Nyxoah, qui consiste à collaborer avec les centres médicaux régionaux d’excellence afin d'élargir l'accès à sa thérapie de stimulation du nerf hypoglosse (HGNS) Genio®, tout en soutenant les normes les plus élevées en matière de soins cliniques, d'éducation et de collaboration scientifique.

Dans le cadre de ce protocole d'accord, Nyxoah et SSMC s'engagent dans des initiatives visant à positionner SSMC comme un centre régional de premier plan pour la thérapie Genio. Ces efforts ont pour but de soutenir le développement d'un programme d'implantation à grand volume axé sur les soins centrés sur le patient.

Parallèlement, cette collaboration prévoit de faire du SSMC un centre régional de formation à la thérapie Genio au Moyen-Orient afin de soutenir la formation des chirurgiens, des médecins spécialistes du sommeil et des professionnels de santé référents de toute la région.

Nyxoah et le SSMC sont également engagés dans des discussions visant à explorer la recherche clinique et la collaboration dans le domaine de l'apnée du sommeil et de la prise en charge des maladies chroniques et métaboliques.

Olivier Taelman, Chief Executive Officer de Nyxoah, a commenté : “Compte tenu de la forte prévalence de l'apnée obstructive du sommeil au Moyen-Orient, cette initiative soutient notre vision d'offrir de nouvelles options de traitement aux patients de la région et d'explorer davantage l'impact de la prise en charge avancée de l'AOS sur les maladies chroniques et métaboliques telles que le diabète de type 2. Notre engagement actif auprès de Sheikh Shakhbout Medical City reflète notre stratégie de partenariat avec des institutions de premier plan afin de mettre en place des programmes cliniques durables, de soutenir la formation des médecins et de contribuer à l'amélioration des soins prodigués aux patients atteints d'apnée obstructive du sommeil.”

Dr. Marwan Al Kaabi, Chief Executive Officer de Sheikh Shakhbout Medical City, a ajouté : “À Sheikh Shakhbout Medical City, nous nous engageons à promouvoir des soins spécialisés et de haute qualité grâce à l'excellence clinique, à l'éducation et à la recherche. Notre collaboration avec Nyxoah soutient nos efforts visant à développer davantage notre expertise dans les thérapies innovantes contre l'apnée du sommeil et à servir de centre régional de référence pour la formation et les échanges scientifiques.”

À propos de Nyxoah
Nyxoah opère dans le secteur des technologies médicales. Elle se concentre sur le développement et la commercialisation de solutions innovantes destinées à traiter le Syndrome d’Apnées Obstructives du Sommeil (SAOS). La principale solution de Nyxoah est le système Genio^®, une thérapie de neurostimulation du nerf hypoglosse sans sonde et sans batterie qui a reçu le marquage CE, centrée sur le patient et destinée à traiter le Syndrome d’Apnées Obstructives du Sommeil (SAOS), le trouble respiratoire du sommeil le plus courant au monde. Ce dernier est associé à un risque accru de mortalité et des comorbidités, dont les maladies cardiovasculaires. La visions de Nyxoah est que les patients souffrant de SAOS doivent pouvoir profiter de nuits réparatrices et vivre pleinement leur vie.

À la suite de la finalisation probante de l’étude BLAST OSA, le système Genio^® a reçu le marquage européen CE en 2019. Nyxoah a réalisé avec succès deux IPO : l’une sur Euronext Bruxelles en septembre 2020 et l’autre sur le NASDAQ en juillet 2021. Grâce aux résultats positifs de l'étude BETTER SLEEP, Nyxoah a reçu le marquage CE pour l’extension de ses indications thérapeutiques aux patients souffrant de collapsus concentrique complet (CCC), pour lesquels les thérapies concurrentes sont actuellement contre-indiquées. En outre, la Société a annoncé les résultats positifs de l'étude pivot DREAM IDE et l'obtention de l'autorisation de la FDA pour un sous-groupe de patients adultes atteints d'AOS modérée à sévère avec un IAH supérieur ou égal à 15 et inférieur ou égal à 65.

Pour plus d’informations, visitez www.nyxoah.com

Attention – Marquage CE depuis 2019. Approuvé par la FDA en août 2025 en tant que dispositif disponible uniquement sur prescription médicale.

DÉCLARATIONS PROSPECTIVES
Certaines déclarations, convictions et opinions contenues dans ce communiqué de presse sont de nature prospective et reflètent les attentes actuelles de la Société ou, le cas échéant, de ses administrateurs ou de sa direction concernant le système Genio ; les études cliniques prévues et en cours sur le système Genio ; les avantages potentiels du système Genio ; les objectifs de Nyxoah en matière de développement, de parcours réglementaire et d'utilisation potentielle du système Genio ; la stratégie de commercialisation de la société et son entrée sur le marché américain ; et les résultats d'exploitation, la situation financière, la liquidité, les performances, les perspectives, la croissance et les stratégies de la société. De par leur nature, les déclarations prospectives comportent un certain nombre de risques, d'incertitudes, d'hypothèses et d'autres facteurs qui pourraient faire en sorte que les résultats ou événements réels diffèrent sensiblement de ceux exprimés ou sous-entendus dans les déclarations prospectives. Ces risques, incertitudes, hypothèses et facteurs pourraient avoir une incidence défavorable sur les résultats et les effets financiers des plans et événements décrits dans le présent document. En outre, ces risques et incertitudes comprennent, sans s'y limiter, les risques et incertitudes énoncés dans la section « Facteurs de risque » du rapport annuel de la société sur le formulaire 20-F pour l'exercice clos le 31 décembre 2024, déposé auprès de la Securities and Exchange Commission (« SEC ») le 20 mars 2025, et dans les rapports ultérieurs que la Société dépose auprès de la SEC. Une multitude de facteurs, y compris, mais sans s'y limiter, les changements dans la demande, la concurrence et la technologie, peuvent faire en sorte que les événements, les performances ou les résultats réels diffèrent considérablement de toute évolution prévue. Les déclarations prospectives contenues dans le présent communiqué de presse concernant les tendances ou activités passées ne constituent pas des garanties de performances futures et ne doivent pas être interprétées comme une indication que ces tendances ou activités se poursuivront à l'avenir. En outre, même si les résultats ou développements réels sont conformes aux déclarations prospectives contenues dans le présent communiqué de presse, ces résultats ou développements ne sont pas nécessairement indicatifs des résultats ou développements futurs. Aucune déclaration ni garantie n'est faite quant à l'exactitude ou à l'équité de ces déclarations prospectives. Par conséquent, la Société décline expressément toute obligation ou engagement de publier des mises à jour ou des révisions des déclarations prospectives contenues dans le présent communiqué de presse à la suite d'un changement dans les attentes ou d'un changement dans les événements, les conditions, les hypothèses ou les circonstances sur lesquels ces déclarations prospectives sont fondées, sauf si la loi ou la réglementation l'exige expressément. Ni la Société, ni ses conseillers ou représentants, ni aucune de ses filiales, ni aucun des dirigeants ou employés de ces personnes ne garantissent que les hypothèses sous-jacentes à ces déclarations prospectives sont exemptes d'erreurs, et n'acceptent aucune responsabilité quant à l'exactitude future des déclarations prospectives contenues dans le présent communiqué de presse ou à la réalisation effective des développements prévus. Vous ne devez pas vous fier indûment aux déclarations prospectives, qui ne sont valables qu'à la date du présent communiqué de presse.

Contacts :

Nyxoah
John Landry, CFO
[email protected]

Rémi Renard
Head of Investor Relations & Corporate Communication
[email protected]

Pièce jointe

• FRENCH_SSMC Partnership PR

GLOBENEWSWIRE (Distribution ID 1001165373)

Nyxoah Announces the Signature of a Memorandum of Understanding with Sheikh Shakhbout Medical City Hospital to Improve OSA Therapy Management and Accelerate Access to Genio in the Middle East

Mont-Saint-Guibert, Belgium – February 18, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced continued progress in strengthening its presence in the Middle East through the signature of a Memorandum of Understanding (MoU) with Sheikh Shakhbout Medical City (SSMC), a flagship hospital in the United Arab Emirates for serious and complex care and a subsidiary of PureHealth, the largest healthcare group in the Middle East. This MoU reflects Nyxoah’s strategic focus on working with leading regional medical centers to expand access to its Genio® hypoglossal nerve stimulation (HGNS) therapy, while supporting the highest standards of clinical care, education, and scientific collaboration.

As part of this MoU, Nyxoah and SSMC are engaged in initiatives aimed at positioning SSMC as a leading regional center for Genio therapy. These efforts are intended to support the development of a high-volume implant program with a strong focus on patient-centered care.

In parallel, the collaboration includes plans to establish SSMC as a regional training hub for Genio therapy in the Middle East to support the education of surgeons, sleep physicians, and referring healthcare professionals from across the region.

Nyxoah and SSMC are also engaged in discussions to explore clinical research and collaboration in the field of sleep apnea, chronic and metabolic disease management.

Olivier Taelman, Chief Executive Officer of Nyxoah, commented: “Given the high prevalence of Obstructive Sleep Apnea in the Middle East, this initiative supports our vision to offer new treatment options to patients in the region and further explore the impact of advanced OSA management on chronic and metabolic diseases such as type 2 diabetes. Our active engagement with Sheikh Shakhbout Medical City reflects our strategy of partnering with leading institutions to build sustainable clinical programs, support physician education, and contribute to the advancement of care for patients living with obstructive sleep apnea.”

Dr. Marwan Al Kaabi, Chief Executive Officer of Sheikh Shakhbout Medical City, added: “At Sheikh Shakhbout Medical City, we are committed to advancing specialized, high-quality care through clinical excellence, education, and research. Our collaboration with Nyxoah supports our efforts to further develop expertise in innovative sleep apnea therapies and to serve as a regional reference center for training and scientific exchange.”

About Nyxoah

Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the FDA for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device.

Forward-looking statements

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or management’s current expectations regarding the Genio system; the potential advantages of the Genio system; Nyxoah’s goals with respect to the potential use of the Genio system; the Company's commercialization strategy and entrance to the U.S. market; the Company's results of operations, financial condition, liquidity, performance, prospects, growth, future revenue and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2025 and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward- looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Contacts:
Nyxoah
John Landry, CFO
[email protected]

Rémi Renard
Head of Investor Relations & Corporate Communication
[email protected]

Attachment

• ENGLISH_SSMC Partnership PR

GLOBENEWSWIRE (Distribution ID 1001165373)

Nyxoah Fera une Présentation lors de la 44^ème Conférence Annuelle J.P. Morgan Healthcare

Mont–Saint–Guibert, Belgique – 29 décembre 2025, 22h05 CET / 16h05 ET – Nyxoah SA (Euronext Bruxelles/Nasdaq : NYXH) (« Nyxoah » ou la « Société ») une société de technologie médicale spécialisée dans le développement et la commercialisation de solutions innovantes pour le traitement de l'Apnée Obstructive du Sommeil (« AOS ») par neuromodulation, a annoncé aujourd'hui que le management présentera lors de la 44e conférence annuelle J.P. Morgan Healthcare à San Francisco, le jeudi 15 janvier 2026. La présentation de la Société débutera à 12h00 PT.

Une retransmission audio en direct de la présentation sera disponible en ligne sur la page Relations investisseurs du site Web de la société à l'adresse investors.nyxoah.com.

À propos de Nyxoah
Nyxoah opère dans le secteur des technologies médicales. Elle se concentre sur le développement et la commercialisation de solutions innovantes destinées à traiter le Syndrome d’Apnées Obstructives du Sommeil (SAOS). La principale solution de Nyxoah est le système Genio^®, une thérapie de neurostimulation du nerf hypoglosse sans sonde et sans batterie qui a reçu le marquage CE, centrée sur le patient et destinée à traiter le Syndrome d’Apnées Obstructives du Sommeil (SAOS), le trouble respiratoire du sommeil le plus courant au monde. Ce dernier est associé à un risque accru de mortalité et des comorbidités, dont les maladies cardiovasculaires. La visions de Nyxoah est que les patients souffrant de SAOS doivent pouvoir profiter de nuits réparatrices et vivre pleinement leur vie.

À la suite de la finalisation probante de l’étude BLAST OSA, le système Genio^® a reçu le marquage européen CE en 2019. Nyxoah a réalisé avec succès deux IPO : l’une sur Euronext Bruxelles en septembre 2020 et l’autre sur le NASDAQ en juillet 2021. Grâce aux résultats positifs de l'étude BETTER SLEEP, Nyxoah a reçu le marquage CE pour l’extension de ses indications thérapeutiques aux patients souffrant de collapsus concentrique complet (CCC), pour lesquels les thérapies concurrentes sont actuellement contre–indiquées. En outre, la Société a annoncé les résultats positifs de l'étude pivot DREAM IDE et l'obtention de l'autorisation de la FDA pour un sous–groupe de patients adultes atteints d'AOS modérée à sévère avec un IAH supérieur ou égal à 15 et inférieur ou égal à 65.

Pour plus d’informations, visitez www.nyxoah.com

Attention – marquage CE depuis 2019. Approuvé par la FDA en août 2025 en tant que dispositif disponible uniquement sur prescription médicale.

Contacts :

Nyxoah
John Landry, CFO
[email protected]

Rémi Renard
Chief Investor Relations & Corporate Communication Officer
[email protected]

Pièce jointe

• FRENCH_NYXH JP Morgan Conf Advisory PR_2025

GLOBENEWSWIRE (Distribution ID 1001156886)

Nyxoah to Present at the 44^th Annual J.P. Morgan Healthcare Conference

Mont–Saint–Guibert, Belgium – December 29, 2025, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the management team will present at the 44^th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, Jan. 15, 2026. The Company's presentation will begin at 12:00 pm PT.

A live audio webcast of the presentation will be available online on the investor relations page of the Company’s website at investors.nyxoah.com.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient–centered, leadless and battery–free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the FDA for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. FDA approved in August 2025 as prescription–only device.

Contact:

Nyxoah
John Landry, CFO
[email protected]

Rémi Renard
Chief Investor Relations & Corporate Communication Officer
[email protected]

Attachment

• ENGLISH_NYXH JP Morgan Conf Advisory PR_2025

GLOBENEWSWIRE (Distribution ID 1001156886)

Nyxoah Announces Issuance of First Tranche of Convertible Bonds

Mont–Saint–Guibert, Belgium – December 19, 2025, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA) through neuromodulation, today announced the issuance of the first tranche of the convertible bond financing entered into with an entity managed by Heights Capital Management (“HCM”) of up to €45 million, as previously announced by the Company on November 13, 2025.

Closing of the first tranche of the convertible bonds’ issuance

On December 18, 2025, the Company issued the first tranche of convertible bonds for a nominal amount of €22.5 million under the subscription agreement entered into with HCM on November 13, 2025, as amended and restated on December 16, 2025. The first tranche consisted of the issuance of 225 convertible bonds (the “First Tranche Bonds”) with a nominal amount of €100,000 each, which were fully subscribed to and paid–up by HCM. Pursuant to the subscription agreement, the Company has paid a subscription fee to HCM equal to 8.0 per cent of the principal amount of the First Tranche Bonds (i.e., €1.8 million), which has been satisfied by set–off against the respective portion of the subscription price of the First Tranche Bonds due by HCM.

The First Tranche Bonds carry an interest rate of 6.5 per cent per annum and have a three–year maturity from issuance with quarterly amortization payments (each a “Scheduled Amortisation Payment Date”) of principal (equal to an amount of €8.500 per First Tranche Bond, except for the final amortization payment which will be equal to €6.500 per First Tranche Bond, each an “Amortised Payment Amount”) and interest. The first Scheduled Amortisation Payment Date will be on February 18, 2026.

In addition to the scheduled amortisation payments, HCM (or any future holders of the majority of the First Tranche Bonds) may, at any time between two Scheduled Amortisation Payment Dates (a “Regular Amortisation Period”), exercise its right to bring forward the payment of up to two Amortised Payment Amounts to a date specified in a notice sent to the Company which shall not be earlier than three business days following the date on which the relevant notice is given. Additionally, HCM (or any future holders of the majority of the First Tranche Bonds) will also have the right to defer the payment of any upcoming Amortised Payment Amount to any subsequent Scheduled Amortisation Payment Date specified in the notice sent to the Company.

HCM may elect to convert the outstanding principal amount under the First Tranche Bonds or any Amortized Payment Amount at any time during the term of the bonds. The initial conversion price for the First Tranche Bonds, which can be modified on a downward basis, shall be equal to €5.00, which represents 125 per cent of the placement price of the shares that have been issued pursuant to the previously announced private placement and registered direct offering (the “Capital Increases”).

Each payment of the Amortised Payment Amounts shall in principle be done in cash at an amount equal to 103 per cent of the principal amount of such Amortised Payment Amount. However, the Company may elect to satisfy its obligation to repay the relevant Amortised Payment Amount by issuing new ordinary shares in the Company to HCM (the “Share Settlement Option”). In case the Company exercises its Share Settlement Option, the issue price for the newly to be issued ordinary shares will be the lower of (a) the conversion price in effect at the time, and (b) 90% of the lower of (i) the VWAP of an ordinary share on the relevant Scheduled Amortisation Payment Date, and (ii) the lowest of the VWAPs of an ordinary share on each of the five consecutive dealing days ending on (and including) such Scheduled Amortisation Payment Date.

More information on the First Tranche Bonds is available in the special report of the board of directors of the Company drawn up in accordance with articles 7:180, 7:191 and 7:193 of the Belgian Code on companies and associations located at https://investors.nyxoah.com/financials.

Second tranche convertible bonds

Pursuant to the subscription agreement, the Company has the option to issue a second tranche of convertible bonds (the “Second Tranche Bonds”) to HCM for an aggregate principal amount of up to €22.5 million if so requested by the Company in the period between July 18, 2026 and August 18, 2026.

The Company and HCM can agree in writing to a lesser aggregate principal amount than €22.5 million for the Second Tranche Bonds issuance.

The obligation for HCM to subscribe to the Second Tranche Bonds on the closing date for the Second Tranche Bonds (the “Second Tranche Closing Date”) shall be subject to certain customary conditions precedent being satisfied (or waived by HCM) prior to or on the Second Tranche Closing Date. More specifically, it is, among others, required that:

• the arithmetic mean (rounded to the nearest whole multiple of U.S.$1.00 (with U.S.$0.50 being rounded upwards)) of the daily traded values of the ordinary shares of the Company on each dealing day comprised in the period of sixty qualifying stock exchange days ending on the qualifying stock exchange date immediately preceding the date of the Company’s request to issue the Second Tranche Bonds is greater than U.S.$1 million (or its equivalent in any other currency); and

• the Company has a last market capitalisation immediately preceding the Second Tranche Closing Date, and an average market capitalisation on each of the 30 consecutive dealing days ending on (and including) the dealing day immediately preceding the Second Tranche Closing Date that are each greater than €240,000,000.

As of December 16, 2025, the conditions precedent relating to the daily traded values, the last market capitalisation and the average market capitalisation were not met. More precisely, as of December 16, 2025, the arithmetic mean of the daily traded values amounted to U.S.$ 772,176, the last market capitalisation amounted to €177,053,883 and the 30–day average market capitalisation amounted to €175,959,735.

The Second Tranche Bonds shall, to the extent applicable, be issued on substantially the same terms as the First Tranche Bonds. The initial conversion price of the Second Tranche Bonds shall be equal to the lowest of the five VWAPs of the ordinary shares of the Company on Euronext Brussels on each of the five dealing days ending on the Second Tranche Closing Date.

Cash runway

The issuance of the First Tranche Bonds and closing of the Capital Increases, together with the second tranche under the Company’s existing credit facility with the European Investment Bank (for which the possibility to draw depends on a revenue milestone that the Company expects to meet in the first half of 2026), will extend the Company’s cash runway into the third quarter of 2026. If, in addition to the foregoing, the Second Tranche Bonds are issued, the Company’s cash runway will be extended by two (2) quarters, into the first quarter of 2027.

The net proceeds from the First Tranche Bonds together with the net proceeds of the Capital Increases will be used (i) to support commercialization activities in the United States and advance the commercialization of the Genio system in the Company’s initial target markets outside the United States; (ii) to continue gathering clinical data and to support physician–initiated clinical research projects related to OSA patient treatments; (iii) to further finance research and development activities related to Genio system upgrades, re–designing the Company’s products for manufacturability and cost reduction initiatives; (iv) to continue to build a pipeline of new technologies and explore potential collaboration opportunities in the field of monitoring and diagnostics for OSA; and (v) for other general corporate purposes, including, but not limited to, working capital, capital expenditures, investments, acquisitions, should the Company choose to pursue any, and collaborations.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient–centered, leadless and battery–free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the FDA for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65.

Caution – CE marked since 2019. FDA approved in August 2025 as prescription–only device.

IMPORTANT INFORMATION

THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW. THIS ANNOUNCEMENT IS FOR GENERAL INFORMATION ONLY AND DOES NOT FORM PART OF ANY OFFER TO SELL OR PURCHASE, OR THE SOLICITATION OF ANY OFFER TO SELL OR PURCHASE, ANY SECURITIES. THE DISTRIBUTION OF THIS ANNOUNCEMENT AND THE OFFER, SUBSCRIPTION, SALE AND PURCHASE OF SECURITIES DESCRIBED IN THIS ANNOUNCEMENT IN CERTAIN JURISDICTIONS MAY BE RESTRICTED BY LAW. ANY PERSONS READING THIS ANNOUNCEMENT SHOULD INFORM THEMSELVES OF AND OBSERVE ANY SUCH RESTRICTIONS.

Forward–looking statements

Certain statements, beliefs and opinions in this press release are forward–looking, which reflect the Company’s or, as appropriate, the Company directors’ or managements’ current expectations regarding the convertible bond financing; the Genio system; the potential advantages of the Genio system; Nyxoah’s goals with respect to the potential use of the Genio system; the Company's commercialization strategy and entrance to the U.S. market; and the Company's results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward–looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward–looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. These risks and uncertainties include, but are not limited to, the satisfaction of the closing conditions required for the Second Tranche Bonds and the corresponding closing, the use of net proceeds from the First Tranche Bonds, the expected sufficiency of the Company’s cash resources and runway, which may not be accurate resulting in the need for additional financing sooner than anticipated, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20–F for the year ended December 31, 2024, filed with the SEC on March 20, 2025 and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward–looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward–looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward–looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward–looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward– looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward–looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward–looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward–looking statements, which speak only as of the date of this press release.

Contacts:

Nyxoah
John Landry, CFO
[email protected]

Attachment

• ENGLISH_Nyxoah SA – Press release First Tranche Bonds (ENG) final)

GLOBENEWSWIRE (Distribution ID 1001145999)